Boston Scientific acquires medical device maker Penumbra in USD14.5b deal
Make us a preferred source
Make us a preferred source on Google
The news: Boston Scientific Corporation agreed to buy medical device maker Penumbra in a deal valued at USD14.5 billion ($21.7 billion) as it expands its portfolio of treatments for cardiovascular diseases.
The numbers: In a press release published Thursday, Boston Scientific said that the cash and stock transaction values Penumbra at USD374 per share, reflecting an enterprise value of approximately $14.5 billion. The figure is around 19% above Penumbra’s closing price on Wednesday.
Stockholders will choose between receiving USD374 in cash or 3.8721 shares of Boston Scientific common stock in the deal which is expected to complete this year.
The context: Penumbra is expected to bring in around USD1.4 billion in revenue for 2025, representing growth in the range of approximately 17.3% - 17.5% over the prior fiscal year.
The acquisition marks the first major healthcare deal of 2026 and will give Boston Scientific access to Penumbra’s broad portfolio of devices for the treatment of conditions including pulmonary embolism, stroke, deep vein thrombosis, acute limb ischemia, heart attack and aneurysms.
Penumbra’s chairman and CEO, Adam Elsesser, will join the board of Boston Scientific upon deal close.
The source: Boston Scientific
